Arcus Biosciences, Inc. (NYSE:RCUS) Q3 2023 Earnings Conference Call November 7, 2023 5:00 PM ET

Company Participants

Pia Eaves - Head of Investor Relations And Strategy

Terry Rosen - Co-Founder, Chairman & CEO

Dimitry Nuyten - Chief Medical Officer

Jennifer Jarrett - COO & Director

Robert Goeltz - Principal Financial & Accounting Officer & CFO

Juan Jaen - President and Head of Research

Conference Call Participants

Yigal Nochomovitz - Citigroup

Jonathan Miller - Evercore ISI

Peter Lawson - Barclays Bank

Robin Karnauskas - Truist

Kaveri Pohlman - BTIG

Mara Goldstein - Mizuho Securities

Rosemary Li - Cantor Fitzgerald & Co.

Jason Zemanski - Bank of America

Operator

Thank you and welcome to the call. Following prepared remarks from the Company, we will open the call for questions. [Operator instructions] This call is being recorded and will be available on the investors section of the ARCUS website.

I will now turn the meeting over to Pia Eaves, Head of Investor Relations And Strategy

Pia Eaves

Hello everyone and thank you for joining us on today's conference call to discuss ARCUS's third quarter 2023 financial results and pipeline updates, including today's presentation of data from our EDGE Gastric trial at the ASCO monthly plenary.

Today you will hear from Terry Rosen, Chief Executive Officer, Dimitry Nuyten, Chief Medical Officer, Jennifer Jarrett, Chief Operating Officer, and Bob Goeltz, Chief Financial Officer. For Q&A, we will also be joined by Juan Jaen, President and Head of Research.

I'd like to remind you that on this call, management will be making forward-looking statements, including statements about our cash runway, our investigational products, our expected clinical development milestones and timelines, and the potential market opportunity and drug-treatable population of any indications being pursued by our program.

All statements, other than historical facts, involve risks and uncertainties that may cause our actual results to differ. Those risks and uncertainties are described in our most recent quarterly report on Form 10-Q that has been filed with the SEC. We strongly encourage you to review the filing. For today's call, please refer to our latest corporate deck, which can be found on the investor section of our website.

With that, I'll turn the call over to Terry.

Terry Rosen

Thank you very much, Pia, and thank you all for those who are on the line. This is the first quarterly earnings call we've had in some time. So in addition to the Domvanalimab data that was just presented at Ascol Plenary, we're also going to discuss our other upcoming data readouts, specifically for AB521, our potentially best-in-class HIF-2a inhibitor, and Quemliclustat, our first-in-class small molecule CD73 inhibitor, both of which we'll be sharing data with you just in the next few months.